<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: European Commission approves AstraZeneca&#8217;s Bydureon BCise device	</title>
	<atom:link href="https://ukinvestormagazine.co.uk/european-commission-approves-astrazenecas-bydureon-bcise-device/feed/" rel="self" type="application/rss+xml" />
	<link>https://ukinvestormagazine.co.uk/european-commission-approves-astrazenecas-bydureon-bcise-device/</link>
	<description>UK Investor Magazine provides breaking financial news and investment ideas</description>
	<lastBuildDate>Tue, 30 Oct 2018 10:43:41 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>
	<item>
		<title>
		By: AstraZeneca sells rights to Grunenthal - UK Investor Magazine		</title>
		<link>https://ukinvestormagazine.co.uk/european-commission-approves-astrazenecas-bydureon-bcise-device/#comment-8733</link>

		<dc:creator><![CDATA[AstraZeneca sells rights to Grunenthal - UK Investor Magazine]]></dc:creator>
		<pubDate>Tue, 30 Oct 2018 10:43:41 +0000</pubDate>
		<guid isPermaLink="false">https://ukinvestormagazine.co.uk/?p=13680#comment-8733</guid>

					<description><![CDATA[[&#8230;] this year, the European Commission approved AstraZeneca’s Bydureon BCise devise. Equally, its hairy cell leukaemia treatment was approved by the [&#8230;]]]></description>
			<content:encoded><![CDATA[<p>[&#8230;] this year, the European Commission approved AstraZeneca’s Bydureon BCise devise. Equally, its hairy cell leukaemia treatment was approved by the [&#8230;]</p>
]]></content:encoded>
		
			</item>
	</channel>
</rss>
